Sel Biochem

Sel Biochem is a leading Chinese biopharmaceutical and chemical manufacturing company specializing in the production of active pharmaceutical ingredients (APIs), intermediates, and veterinary drugs. The company is recognized as the world's largest manufacturer of pleuromutilin and its derivative tiamulin fumarate, which are critical components for both human and animal antibiotics. Notably, Sel Biochem is the primary commercial supplier of the key intermediate for lefamulin (Xenleta), a first-in-class pleuromutilin antibiotic developed by Nabriva Therapeutics for community-acquired bacterial pneumonia. As a subsidiary of Zhejiang University Sunny Technology Co., Ltd., the company leverages advanced fermentation and synthetic biology technologies to produce high-purity biochemicals, vitamins, and coenzymes. Sel Biochem operates major manufacturing bases in Xinjiang and Jiangsu, serving as a significant CDMO partner for global pharmaceutical firms.